Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN5713 + REGN5715
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
REGN5713 + REGN5715 is a combination of two human monoclonal antibodies developed to treat allergic responses to birch pollen, specifically targeting individuals with **birch (Betula) pollen allergy**. These antibodies are designed to bind and block Bet v 1, the major allergenic protein in birch pollen, thereby preventing its interaction with IgE on mast cells and basophils, and reducing the subsequent allergic cascade. REGN5713 and REGN5715 bind noncompetitively to distinct epitopes on Bet v 1, thereby delivering a broad blockade of this allergen. The combination has shown efficacy in reducing ocular and nasal allergy symptoms following birch pollen exposure in clinical studies, with demonstrated safety and tolerability in phase 1 and phase 3 trials. It is developed and trialed by Regeneron Pharmaceuticals[2][4][5][7][9].
- Other names
- REGN5713-5715REGN-5713-5715REGN 5713-5715
02
Targets
Bet v 1
Beyond the preview
Go deeper on REGN5713 + REGN5715.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN5713 + REGN5715.